BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ifinatamab Deruxtecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ifinatamab Deruxtecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04145622-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04145622)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: Study of Ifinatamab 
 Deruxtecan (DS-7300a\, I-DXd) in Participants With Advanced Solid Malignan
 t Tumors\nEstimated primary completion: 30 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04145622
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405151-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20270612
DTEND;VALUE=DATE:20270613
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07405151)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: A Clinical Trial of Ifinatamab Deruxtecan in People With 
 Advanced Esophageal Cancer (MK-3475-06F)\nEstimated primary completion: 12
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07405151
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362252-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06362252)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study of I-DXd in Combination With Atezolizumab With or Without Car
 boplatin as First-Line Induction or Maintenance in Subjects With Extensive
  Stage-Small Cell Lung Cancer (IDeate-Lung03)\nEstimated primary completio
 n: 20 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifin
 atamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06362252
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study in Participants With Advanced Cancers Associated With Express
 ion of DLL3 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04471727
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203210-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06203210)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Small Cell Lung Cancer.\nStud
 y: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice
  in Subjects With Relapsed Small Cell Lung Cancer\nEstimated primary compl
 etion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06203210
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644781-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06644781)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Esophageal Squamous Cell Carc
 inoma.\nStudy: A Study of Ifinatamab Deruxtecan in Subjects With Pretreate
 d Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate
 -Esophageal01)\nEstimated primary completion: 1 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06644781
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925737-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06925737)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3.\nStudy: A Clinical Study of If
 inatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-
 2400-001)\nEstimated primary completion: 26 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06925737
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330064-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20280725
DTEND;VALUE=DATE:20280726
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06330064)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Study to Evaluate 
 the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With 
 Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)\nEstimated primar
 y completion: 25 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06330064
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925268-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT07925268)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2.\nStudy: Study of Ifinatamab De
 ruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer\n
 Estimated primary completion: 30 November 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07925268
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) an
 d Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory E
 xtensive-Stage Small Cell Lung Cancer (MK-6070-002)\nEstimated primary com
 pletion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06780137
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (M
 K-2400) in People With Small Cell Lung Cancer (MK-6070-003)\nEstimated pri
 mary completion: 29 November 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07227597
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630974-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20310817
DTEND;VALUE=DATE:20310818
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07630974)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Study of Ifinatama
 b Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid T
 umors (MK-9999-01D/LIGHTBEAM-U01)\nEstimated primary completion: 17 August
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-der
 uxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07630974
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863272-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06863272)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Clinical Study of 
 Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Tr
 eat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDe
 ate-Prostate02)\nEstimated primary completion: 1 October 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06863272
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: Substudy 06E: Umbrella Study of Combination Therapies in 
 Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)\nEstimated primary completion
 : 4 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifi
 natamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06780111
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembroliz
 umab (MK-3475) With or Without Chemotherapy When Used With Investigational
  Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung
  Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion:
  13 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/if
 inatamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04165070
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780098-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20320302
DTEND;VALUE=DATE:20320303
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780098)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Substudy 01I: A Study of Investigational Agents in Participants Wit
 h Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) 
 (MK-3475-01I/KEYMAKER-U01I)\nEstimated primary completion: 2 March 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678
 0098
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780085-2527@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780085)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Investigational Agents in Participants With Previously T
 reated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01
 H/KEYMAKER-U01)\nEstimated primary completion: 12 March 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06780085
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
